#USA #New York #Fortress Biotech #Pomerantz LLC #FBIO

Pomerantz Law Firm Investigates Fortress Biotech Inc.

Pomerantz LLP, a leading law firm in corporate and securities class action litigation, has initiated an investigation into the potential misconduct of Fortress Biotech Inc. (NASDAQ: FBIO). This inquiry targets possible securities fraud and other unlawful business practices that might have affected investors within the company.

The probe comes after a significant decline in Fortress's stock price following news from the U.S. Food and Drug Administration (FDA). On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, announced that they received a Complete Response Letter (CRL) concerning the New Drug Application for CUTX-101. The FDA's letter expressed concerns regarding observed deficiencies in current Good Manufacturing Practice (cGMP) at the facility responsible for the production of CUTX-101. As a direct result of this news, Fortress’s stock plummeted by $1.14, representing a loss of 30.81%, closing at just $2.56 per share that day.

The investigation by Pomerantz LLP aims to gather facts surrounding the actions of Fortress, its officers, and directors to determine whether there were violations of securities laws that cost investors financially. Affected investors are encouraged to connect with Danielle Peyton, who is leading the investigation, to explore their options further. Interested parties can reach out via her email at [email protected] or call 646-581-9980, extension 7980.

Pomerantz LLP was established over 85 years ago and is recognized as a pioneer in the fields of securities class actions and corporate litigation. The firm is also known for its significant recoveries on behalf of victims of securities fraud and corporate misconduct. It has successfully secured multimillion-dollar damages awards for class members over its extensive history.

Background on Fortress Biotech

Fortress Biotech, Inc. focuses on the development of innovative therapies for patients with unmet medical needs. The company's therapeutic offerings range from assisting in the development of new drugs to direct commercialization. Their subsidiary, Cyprium Therapeutics, plays a crucial role in advancing these medical therapies. The FDA's recent letter regarding CUTX-101 poses a substantial challenge to Fortress, underscoring the intricacies of navigating regulatory compliance in biotechnology.

Fortress continues to represent interests within the biotech industry, but the implications of the FDA response and the ensuing stock market reaction could present serious challenges ahead. Investors might need to evaluate their positions carefully as the situation unfolds.

The Role of Pomerantz LLP

Pomerantz LLP stands out as a reputable player in the legal landscape for investors facing financial losses due to corporate misdeeds. The firm diligently advocates for the rights of shareholders and works to uncover truths that might not be immediately visible to the public or investors. As the investigation into Fortress Biotech proceeds, the spotlight on the company’s compliance practices and transparency will likely intensify.

In summary, those invested in Fortress Biotech Inc. should stay informed as new developments emerge from this ongoing investigation. The outcome could lead to potential recovery for investors if securities fraud is confirmed. Interested parties are urged to consider their legal options in light of the situation.

Conclusion

Investors are encouraged to remain vigilant regarding developments with Fortress Biotech Inc., especially following the FDA’s critical response and the stock's significant downturn. The situation is evolving, and the investigations undertaken by firms like Pomerantz LLP may yield important insights that could impact investor decisions moving forward.